Metabolic tumor burden quantified on [18F]FDG PET/CT improves TNM staging of lung cancer patients.

about

Metabolic tumor burden quantified on [18F]FDG PET/CT improves TNM staging of lung cancer patients.

Item

http://www.wikidata.org/entity/Q47735250

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Metabolic tumor burden quantif ...... aging of lung cancer patients.

@en

Metabolic tumor burden quantif ...... aging of lung cancer patients.

@nl

type

Item

label

Metabolic tumor burden quantif ...... aging of lung cancer patients.

@en

Metabolic tumor burden quantif ...... aging of lung cancer patients.

@nl

prefLabel

Metabolic tumor burden quantif ...... aging of lung cancer patients.

@en

Metabolic tumor burden quantif ...... aging of lung cancer patients.

@nl

P1476

Metabolic tumor burden quantif ...... aging of lung cancer patients.

@en

P2093

Filipe Caseiro Alves

http://www.w3.org/2001/XMLSchema#string

Gracinda Costa

http://www.w3.org/2001/XMLSchema#string

J M Nascimento Costa

http://www.w3.org/2001/XMLSchema#string

João Pedroso de Lima

http://www.w3.org/2001/XMLSchema#string

Margarida Marques

http://www.w3.org/2001/XMLSchema#string

Paula Lapa

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis

Evaluating the yield of medical tests.

Prognostic factors in non-small cell lung cancer: a decade of progress.

Metabolic tumor volume is an independent prognostic factor in patients treated definitively for non-small-cell lung cancer

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial.

A new PET/CT volumetric prognostic index for non-small cell lung cancer

Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer.

Variations in PET/CT methodology for oncologic imaging at U.S. academic medical centers: an imaging response assessment team survey.

Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer.

Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.

P2888

s00259-017-3789-y

P304

2169-2178

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00259-017-3789-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bárbara Oliveiros

Jorge Isidoro

P577

2017-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28785842

http://www.w3.org/2001/XMLSchema#string